Closed Loop testing if dose-optimisation app for Zestril can improve hypertension

16 May 2024
firstwordpharma.com
AHAClinical Study
Closed Loop Medicine and Pharmanovia on Thursday announced the launch of the OptiZest study to test a drug-plus-software combination therapy for hypertension. The trial start is the result of a 2023 partnership aimed at co-developing and launching precision medicine combination treatments.
The study will evaluate whether a personalised dose of Zestril (lisinopril) can improve blood pressure control for patients at home when combined with Closed Loop's Software-as-a-Medical Device (SaMD) dosing optimisation technology. The trial has recruited its first patient.
Pharmanovia's CEO James Burt said the proof-of-concept study "sets the stage for development and launch of one of the first drug and software combination products for hypertension," which will enable clinicians to "efficiently personalise treatments for patients and seek to optimise the balance between efficacy and unwanted side effects."
Positive reception
The partnership builds on recent study findings published in the Journal of the American Heart Association demonstrating the ability of Closed Loop's SaMD platform to achieve blood pressure control, minimise side effects and support high medication adherence when combined with the calcium channel blocker amlodipine.
A FirstWord snap-poll fielded to cardiologists in February also found a positive reception to the potential integration of such a tool that can enable better dosing of hypertension meds (see Physician Views Results: App-enabled precision medicine? Yes please, say cardiologists).
In March, Closed Loop signed a deal with Teva's UK unit to use its SaMD platform to enhance dosing precision and improve drug efficacy and outcomes for "specific chronic disorders."
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.